Darnitsa pharmaceutical company in 2018 invested about EUR3.5 million in development and research (R&D), Dmytro Shymkiv, the head of the board of directors of Darnitsa Group, has said.
“Every year we invest about 10% of gross income in development and research. In 2018 the amount of such investments totaled EUR 3.5 million. In total, Darnitsa invested about EUR 200 million in development,” he said at a press conference in Kyiv.
Shymkiv said that in 2020-2022 Darnitsa plans to conduct 9-12 drug bioequivalence studies.
Since 2016, the company has completed eight such studies.
According to him, the development strategy of Darnitsa provides for three priority areas of the product portfolio: cardiology, neurological drugs, and pain therapy.
In 2019, the pharmaceutical company plans to bring 11 brands to the market, in 2020 some 14. In 2018, Darnitsa brought ten brands to the market.
Currently, the company’s product portfolio comprises 250 types of finished medicines.
Darnitsa pharmaceutical company is one of the ten largest pharmaceutical manufacturers in Ukraine and the top ten largest hospital suppliers. Its ultimate beneficiary is Hlib Zahoriy.
